Bias as a threat to the validity of cancer molecular-marker research
Top Cited Papers
- 1 February 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (2) , 142-149
- https://doi.org/10.1038/nrc1550
Abstract
Claims that molecular markers can accurately diagnose cancer have recently been disputed; some prominent results have not been reproduced and bias has been proposed to explain the original observations. As new '-omics' fields are explored to assess molecular markers for cancer, bias will increasingly be recognized as the most important 'threat to validity' that must be addressed in the design, conduct and interpretation of such research.Keywords
This publication has 49 references indexed in Scilit:
- High-resolution serum proteomic patterns for ovarian cancer detectionEndocrine-Related Cancer, 2004
- Running before we can walk?Nature, 2004
- Bias in analytic researchPublished by Elsevier ,2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2003
- Developing Molecular Biomarkers for CancerScience, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- The State of Outcome Research: Are We on Target?New England Journal of Medicine, 1989
- Mortality and Reoperation after Open and Transurethral Resection of the Prostate for Benign Prostatic HyperplasiaNew England Journal of Medicine, 1989